RA Capital Management - Q2 2022 holdings

$3.75 Billion is the total value of RA Capital Management's 88 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 37.5% .

 Value Shares↓ Weighting
ASND  ASCENDIS PHARMA A/Ssponsored adr$703,512,000
-20.8%
7,567,9000.0%18.76%
-3.2%
BIIB  BIOGEN INC$148,269,000
-3.2%
727,0240.0%3.95%
+18.3%
 CYTEK BIOSCIENCES INC$143,578,000
-0.5%
13,381,0540.0%3.83%
+21.6%
AVTE  AEROVATE THERAPEUTICS INC$129,166,000
-14.7%
8,263,9820.0%3.44%
+4.2%
DAWN BuyDAY ONE BIOPHARMACEUTICALS I$126,027,000
+109.6%
7,040,622
+16.2%
3.36%
+156.1%
TVTX  TRAVERE THERAPEUTICS INC$119,283,000
-6.0%
4,922,9410.0%3.18%
+14.9%
JANX  JANUX THERAPEUTICS INC$105,869,000
-14.9%
8,670,6440.0%2.82%
+4.1%
PCVX  VAXCYTE INC$99,687,000
-9.9%
4,581,2030.0%2.66%
+10.1%
IMGN  IMMUNOGEN INC$97,837,000
-5.5%
21,741,4580.0%2.61%
+15.5%
NKTX BuyNKARTA INC$96,159,000
+50.8%
7,805,129
+39.2%
2.56%
+84.2%
BLU  BELLUS HEALTH INC NEW$94,528,000
+34.3%
10,230,2740.0%2.52%
+64.1%
ITOS  ITEOS THERAPEUTICS INC$90,996,000
-36.0%
4,417,2590.0%2.43%
-21.8%
VERU NewVERU INC$89,270,0007,900,000
+100.0%
2.38%
 DICE THERAPEUTICS INC$80,842,000
-18.9%
5,208,9110.0%2.16%
-0.9%
NewPEPGEN INC$80,750,0008,131,952
+100.0%
2.15%
FMTX  FORMA THERAPEUTICS HLDGS INC$62,090,000
-25.9%
9,011,6510.0%1.66%
-9.5%
ACRS BuyACLARIS THERAPEUTICS INC$61,403,000
+95.9%
4,398,453
+142.0%
1.64%
+139.3%
PNT  POINT BIOPHARMA GLOBAL INC$61,311,000
-14.6%
9,003,0180.0%1.64%
+4.4%
CLDX  CELLDEX THERAPEUTICS INC NEW$55,942,000
-20.8%
2,075,0000.0%1.49%
-3.2%
WVE BuyWAVE LIFE SCIENCES LTD$55,907,000
+259.5%
17,202,009
+121.2%
1.49%
+339.8%
VOR  VOR BIOPHARMA INC$55,271,000
-17.7%
11,120,9730.0%1.47%
+0.5%
KNTE  KINNATE BIOPHARMA INC$53,771,000
+12.0%
4,264,1440.0%1.43%
+36.8%
 TYRA BIOSCIENCES INC$51,741,000
-33.2%
7,236,4540.0%1.38%
-18.3%
GHRS BuyGH RESEARCH PLCordinary shares$48,886,000
-44.6%
4,898,373
+1.5%
1.30%
-32.3%
GERN  GERON CORP$46,696,000
+14.0%
30,126,2990.0%1.24%
+39.3%
NTRA  NATERA INC$46,437,000
-12.9%
1,310,2890.0%1.24%
+6.4%
ABOS  ACUMEN PHARMACEUTICALS INC$45,923,000
+20.2%
9,770,7730.0%1.22%
+46.8%
NSTG NewNANOSTRING TECHNOLOGIES$45,523,0003,584,478
+100.0%
1.21%
 RXSIGHT INC$42,983,000
+13.7%
3,052,7960.0%1.15%
+38.9%
ENTA SellENANTA PHARMACEUTICALS INC$42,389,000
-38.2%
896,724
-7.0%
1.13%
-24.6%
 ELIEM THERAPEUTICS INC$39,716,000
-64.0%
13,150,8490.0%1.06%
-56.0%
RLMD  RELMADA THERAPEUTICS INC$37,980,000
-29.6%
2,000,0000.0%1.01%
-14.0%
TIL BuyINSTIL BIO INC$35,439,000
-32.3%
7,670,793
+57.5%
0.94%
-17.3%
 ICOSAVAX INC$34,172,000
-18.6%
5,963,5650.0%0.91%
-0.5%
RNA  AVIDITY BIOSCIENCES INC$31,492,000
-21.3%
2,167,3910.0%0.84%
-3.8%
DSGN  DESIGN THERAPEUTICS INC$30,613,000
-13.3%
2,186,6360.0%0.82%
+5.8%
BuyAN2 THERAPEUTICS INC$29,050,000
-47.4%
3,748,389
+2.2%
0.78%
-35.7%
RCKT  ROCKET PHARMACEUTICALS INC$28,994,000
-13.2%
2,107,1490.0%0.77%
+6.0%
EYPT  EYEPOINT PHARMACEUTICALS INC$26,526,000
-35.2%
3,370,5060.0%0.71%
-20.9%
ETNB Buy89BIO INC$25,060,000
+33.9%
7,782,669
+56.7%
0.67%
+63.7%
STSA  SATSUMA PHARMACEUTICALS INC$24,485,000
+8.9%
5,914,2520.0%0.65%
+33.3%
PMVP  PMV PHARMACEUTICALS INC$24,371,000
-31.6%
1,710,2650.0%0.65%
-16.3%
VERA SellVERA THERAPEUTICS INCcl a$21,488,000
-53.5%
1,578,820
-19.7%
0.57%
-43.2%
VRNA  VERONA PHARMA PLCsponsored ads$21,369,000
-16.0%
5,100,0000.0%0.57%
+2.7%
RYTM  RHYTHM PHARMACEUTICALS INC$20,215,000
-64.0%
4,871,0670.0%0.54%
-56.0%
 TENAYA THERAPEUTICS INC$19,995,000
-52.2%
3,551,5080.0%0.53%
-41.6%
DYN  DYNE THERAPEUTICS INC$19,271,000
-28.7%
2,805,0450.0%0.51%
-12.9%
NewHILLEVAX INC$19,237,0001,760,019
+100.0%
0.51%
GH  GUARDANT HEALTH INC$19,217,000
-39.1%
476,3800.0%0.51%
-25.7%
 PARDES BIOSCIENCES INC$18,957,000
-57.5%
6,175,0380.0%0.50%
-48.1%
HOWL  WEREWOLF THERAPEUTICS INC$17,554,000
-7.0%
4,291,8810.0%0.47%
+13.6%
 DA32 LIFE SCNCE$14,535,000
-0.3%
1,500,0000.0%0.39%
+22.0%
CNCE BuyCONCERT PHARMACEUTICALS INC$13,923,000
+36.2%
3,307,203
+9.0%
0.37%
+66.4%
MIST  MILESTONE PHARMACEUTICALS IN$13,816,000
-4.2%
2,246,5030.0%0.37%
+16.8%
ACHL  ACHILLES THERAPEUTICS PLCsponsored ads$12,637,000
-14.3%
5,014,6870.0%0.34%
+4.7%
BLSA  BCLS ACQUISITION CORP$12,375,000
+0.3%
1,250,0000.0%0.33%
+22.7%
OTIC  OTONOMY INC$11,648,000
-13.3%
5,600,0000.0%0.31%
+6.1%
SellLIANBIOsponsored ads$9,985,000
-64.8%
4,622,574
-39.6%
0.27%
-57.1%
FLACU  FRAZIER LIFESCIENCES ACQU CO$9,870,000
-1.2%
1,000,0000.0%0.26%
+20.6%
 ARYA SCIENCES ACQUISITN$9,720,000
+0.1%
1,000,0000.0%0.26%
+22.2%
RLAY  RELAY THERAPEUTICS INC$9,197,000
-44.0%
549,0550.0%0.24%
-31.8%
 IO BIOTECH INC$8,676,000
-11.9%
1,857,7550.0%0.23%
+7.4%
SLDB  SOLID BIOSCIENCES INC$7,614,000
-48.7%
12,367,8730.0%0.20%
-37.3%
FVAM  5 01 ACQUISITION CORP$7,425,000
+0.5%
750,0000.0%0.20%
+23.0%
SYBX SellSYNLOGIC INC$6,700,000
-58.1%
5,825,858
-12.6%
0.18%
-48.7%
BDTX  BLACK DIAMOND THERAPEUTICS I$6,371,000
-11.2%
2,589,9040.0%0.17%
+8.3%
IPSC SellCENTURY THERAPEUTICS INC$6,357,000
-44.8%
756,821
-17.2%
0.17%
-32.7%
HSAQ  HEALTH SCIENCES ACQ CORP 2$6,225,000
+0.5%
625,0000.0%0.17%
+23.0%
CNTB  CONNECT BIOPHARMA HLDGS LTDads$6,082,000
-71.2%
6,991,0030.0%0.16%
-64.9%
BMEA  BIOMEA FUSION INC$5,990,000
+168.6%
500,0000.0%0.16%
+226.5%
ATHA NewATHIRA PHARMA INC$5,728,0001,878,000
+100.0%
0.15%
SellXILIO THERAPEUTICS INC$4,817,000
-66.0%
1,649,711
-17.6%
0.13%
-58.6%
NewAADI BIOSCIENCE INC$4,719,000383,028
+100.0%
0.13%
FLDM NewSTANDARD BIOTOOLS INC$3,180,0001,987,589
+100.0%
0.08%
TERN NewTERNS PHARMACEUTICALS INC$3,128,0001,261,435
+100.0%
0.08%
ENTX  ENTERA BIO LTD$3,129,000
-53.7%
2,353,0000.0%0.08%
-43.5%
BCAB NewBIOATLA INC$2,941,0001,031,805
+100.0%
0.08%
SellASTRIA THERAPEUTICS INC$2,283,000
-73.0%
760,857
-39.7%
0.06%
-67.0%
SellPYXIS ONCOLOGY INC$2,269,000
-75.4%
953,393
-58.2%
0.06%
-70.1%
ADVM NewADVERUM BIOTECHNOLOGIES INC$2,071,0001,726,019
+100.0%
0.06%
LRMR SellLARIMAR THERAPEUTICS INC$2,022,000
-61.1%
1,031,482
-19.5%
0.05%
-52.2%
ORTX SellORCHARD THERAPEUTICS PLCads$1,776,000
-74.3%
3,040,885
-68.6%
0.05%
-68.9%
SNSE NewSENSEI BIOTHERAPEUTICS$1,642,000723,549
+100.0%
0.04%
CVRX  CVRX INC$1,653,000
+0.4%
275,0000.0%0.04%
+22.2%
OLMA SellOLEMA PHARMACEUTICALS INC$952,000
-55.7%
233,793
-53.7%
0.02%
-46.8%
BOLT NewBOLT BIOTHERAPEUTICS INC$918,000450,141
+100.0%
0.02%
AVRO NewAVROBIO INC$515,000559,600
+100.0%
0.01%
CLBS NewCALADRIUS BIOSCIENCES$399,000752,500
+100.0%
0.01%
CMPX ExitCOMPASS THERAPEUTICS INC$0-532,958
-100.0%
-0.02%
ExitTSCAN THERAPEUTICS INC$0-1,021,764
-100.0%
-0.06%
CGEM ExitCULLINAN ONCOLOGY INC$0-350,000
-100.0%
-0.08%
PHAS ExitPHASEBIO PHARMACEUTICALS INC$0-2,850,000
-100.0%
-0.08%
ExitCUE HEALTH INC$0-750,000
-100.0%
-0.11%
VERV ExitVERVE THERAPEUTICS INC$0-310,284
-100.0%
-0.16%
ALVR ExitALLOVIR INC$0-1,440,525
-100.0%
-0.21%
AKUS ExitAKOUOS INC$0-2,281,249
-100.0%
-0.24%
MORF ExitMORPHIC HLDG INC$0-278,874
-100.0%
-0.24%
CYT ExitCYTEIR THERAPEUTICS INC$0-3,350,506
-100.0%
-0.28%
GRPH ExitGRAPHITE BIO INC$0-2,698,369
-100.0%
-0.30%
KALA ExitKALA PHARMACEUTICALS INC$0-10,874,613
-100.0%
-0.33%
SCPH ExitSCPHARMACEUTICALS INC$0-2,658,583
-100.0%
-0.33%
KDNY ExitCHINOOK THERAPEUTICS INC$0-1,000,000
-100.0%
-0.36%
ExitTANGO THERAPEUTICS INC$0-2,250,000
-100.0%
-0.37%
EWTX ExitEDGEWISE THERAPEUTICS INC$0-2,613,623
-100.0%
-0.55%
KALV ExitKALVISTA PHARMACEUTICALS INC$0-1,930,322
-100.0%
-0.62%
CCXI ExitCHEMOCENTRYX INC$0-1,155,964
-100.0%
-0.63%
CNTA ExitCENTESSA PHARMACEUTICALS PLCsponsored ads$0-3,577,094
-100.0%
-0.70%
NVAX ExitNOVAVAX INC$0-692,794
-100.0%
-1.11%
MGNX ExitMACROGENICS INC$0-6,103,594
-100.0%
-1.17%
MRTX ExitMIRATI THERAPEUTICS INC$0-734,343
-100.0%
-1.32%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-08-15
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q2 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%
Satsuma Pharmaceuticals, Inc.Sold outJune 12, 202300.0%
ARYA Sciences Acquisition Corp VSold outMay 15, 202300.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-15
42024-04-15
SC 13G2024-04-15
SC 13D/A2024-04-12
SC 13G2024-04-12
SC 13D/A2024-04-11
SC 13G2024-04-11
42024-04-04
SC 13G2024-04-04
SC 13G2024-04-01

View RA Capital Management's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (3750533000.0 != 3750535000.0)

Export RA Capital Management's holdings